Kinga K. Smolen

Dr. Kinga K. Smolen

Department of Pediatrics, Division of Infectious Disease, Boston Children’s Hospital Department of Pediatrics, Harvard Medical School, Boston, USA
orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 March 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
ALAmy H Lee
Amy H Lee
CSCasey P Shannon
Casey P Shannon
NANelly Amenyogbe
Nelly Amenyogbe
Tue Bjerg BennikeTue Bjerg Bennike
Tue Bjerg Bennike
JAJoann Arce
Joann Arce
TKTobias R. Kollmann
Tobias R. Kollmann
Systems biology can unravel complex biology but has not been extensively applied to human newborns, a group highly vulnerable to a wide range of diseases. We optimized methods to extract transcriptomic, proteomic, metabolomic, cytokine/chemokine, and single cell immune phenotyping data from <1 ml of blood, a volume readily obtained from newborns. Indexing to baseline and applying innovative integrative computational methods reveals dramatic changes along a remarkably stable developmental trajectory over the first week of life. This is most evident in changes of interferon and complement pathways, as well as neutrophil-associated signaling. Validated across two independent cohorts of newborns from West Africa and Australasia, a robust and common trajectory emerges, suggesting a purposeful rather than random developmental path. Systems biology and innovative data integration can provide fresh insights into the molecular ontogeny of the first week of life, a dynamic developmental phase that is key for health and disease.

31 March 2023 in Science Advances
Verified
Journal Article
Closed access
AVArthur Viode
Arthur Viode
PZPatrick van Zalm
Patrick van Zalm
KSKinga K. Smolen
Kinga K. Smolen
BFBenoit Fatou
Benoit Fatou
DSDavid Stevenson
David Stevenson
ONOn Behalf Of The Impacc Network
On Behalf Of The Impacc Network
We introduce a cost-effective, robust high-throughput–compatible plasma depletion method enabling in-depth profiling of plasma that detects >1300 proteins per run with a throughput of 60 samples per day. The method has been fully validated by processing >3000 samples with no apparent batch effect at a cost for the depletion step of ~$2.5 per sample.

1 October 2006 in Journal of Experimental Biology
Verified
Journal Article
Closed access
PDF file
MSM.-P. Schippers
M.-P. Schippers
RDR. Dukas
R. Dukas
RSR. W. Smith
R. W. Smith
JWJ. Wang
J. Wang
KSKinga K. Smolen
Kinga K. Smolen
GMGrant McClelland
Grant McClelland
SUMMARY: Honeybees, Apis mellifera, gradually increase their rate of forage uptake as they gain foraging experience. This increase in foraging performance has been proposed to occur as a result of learning; however, factors affecting flight ability such as changes in physiological components of flight metabolism could also contribute to this pattern.Thus, the purpose of this study was to assess the contribution of physiological changes to the increase in honeybee foraging performance. We investigated aspects of honeybee flight muscle biochemistry throughout the adult life, from non-foraging hive bees, through young and mature foragers, to old foragers near the end of their lifespan. Two-dimensional gel proteomic analysis on honeybee thorax muscle revealed an increase in several proteins from hive bees to mature foragers including troponin T 10a, aldolase and superoxide dismutase. By contrast, the activities (Vmax)of enzymes involved in aerobic performance, phosphofructokinase, hexokinase,pyruvate kinase and cytochrome c oxidase, did not increase in the flight muscles of hive bees, young foragers, mature foragers and old foragers. However, citrate synthase activity was found to increase with foraging experience. Hence, our results suggest plasticity in both structural and metabolic components of flight muscles with foraging experience.

12 September 2018 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
TGTessa Goetghebuer
Tessa Goetghebuer
KSKinga K. Smolen
Kinga K. Smolen
CACatherine Adler
Catherine Adler
JDJishnu Das
Jishnu Das
TMTrevor McBride
Trevor McBride
AMArnaud Marchant
Arnaud Marchant
Epidemiological studies conducted in low- and high-income countries showed that infants exposed to maternal human immunodeficiency virus (HIV) have a high risk of severe infections. Immune alterations during fetal life have been proposed as a possible mechanism. This prospective study assessed the relative risk of hospitalization for infection in HIV-exposed uninfected (HEU) infants as compared to HIV-unexposed (HU) infants born in a high-income country (HIC). Markers of monocyte activation and levels of pathogen-specific antibodies were measured at birth to identify correlates of infant susceptibility. There were 27 of 132 HEU infants and 14 of 123 HU infants hospitalized for infection during the first year of life (adjusted hazard ratio [aHR] 2.33, 95% confidence interval [CI] 1.10-4.97). Most of this increased risk was associated with the time of initiation of maternal antiretroviral therapy (ART). As compared to HU infants, the risk of hospitalization for infection of HEU infants was 4-fold higher when mothers initiated ART during pregnancy (aHR 3.84, 95% CI 1.69-8.71) and was not significantly increased when ART was initiated before pregnancy (aHR 1.42, 95% CI 0.58-3.48). The activation of newborn monocytes and the reduced transfer of maternal antibodies were most intense following ART initiation during pregnancy, and predicted the risk of infant hospitalization. These observations indicate that initiation of maternal ART before pregnancy reduces the susceptibility of HEU infants born in a HIC to severe infections, and that this effect could be related to the prevention of immune alterations during fetal life.

31 August 2016 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
BABahaa Abu-Raya
Bahaa Abu-Raya
KSKinga K. Smolen
Kinga K. Smolen
FWFabienne Willems
Fabienne Willems
TKTobias R. Kollmann
Tobias R. Kollmann
AMArnaud Marchant
Arnaud Marchant
The transfer of maternal immune factors to the newborn is critical for protection from infectious disease in early life. Maternally acquired passive immunity provides protection until the infant is beyond early life’s increased susceptibility to severe infections, or until active immunity is achieved following infant’s primary immunization. However, as reviewed here, HIV infection alters the transfer of immune factors from HIV-infected mothers to the HIV-exposed newborns and young infants. This may relate to the immune activation in HIV-infected pregnant women, associated with the production of inflammatory cytokines at the materno-fetal interface associated with inflammatory responses in the newborn. We also summarize mother-targeting interventions to improve the health of infants born to HIV-infected women such as immunization during pregnancy and reduction of maternal inflammation. Maternal immunization offers the potential to compensate for the decreased transplacentally transferred maternal antibodies observed in HIV-exposed infants. Current data suggest reduced immunogenicity of vaccines in HIV-infected pregnant women, possibly reducing the protective impact of maternal immunization for HIV-exposed infants. Fortunately, levels of antibodies appear preserved in the breast milk of HIV-infected women, which supports the recommendation to breastfeed during antiretroviral treatment to protect HIV-exposed infants.

1 January 2013 in Clinical and Vaccine Immunology
Verified
Journal Article
Open access
PDF file
BRBrian A. Reikie
Brian A. Reikie
SNShalena Naidoo
Shalena Naidoo
CRCandice E. Ruck
Candice E. Ruck
ASAmy L. Slogrove
Amy L. Slogrove
CBCorena de Beer
Corena de Beer
TKTobias R. Kollmann
Tobias R. Kollmann
HIV-exposed but uninfected (HEU) infants born to HIV-infected mothers from areas in the world with a high burden of infectious disease suffer higher infectious morbidity and mortality than their HIV unexposed uninfected (HUU) peers. Vaccination provides protection from infection. The possibility exists that altered response to vaccination contributes to the higher rate of infection in HEU than in HUU infants. While short-term, cross-sectional studies support this notion, it is unclear whether or not HEU infants develop long-term protective immune responses following the WHO extended program on immunization (EPI). Vaccine-specific antibody responses were compared between HEU and HUU infants from 2 weeks until 2 years of age in a longitudinal South African cohort. Total IgG and antibodies specific for Bordetella pertussis , Haemophilus influenzae type b (Hib), tetanus toxoid, hepatitis B virus (HepB), and measles virus were measured at multiple time points throughout the first 2 years of life. Prevaccine antibodies (maternal antibodies passively acquired) specific for tetanus were lower in HEU than in HUU infants, while prevaccine antibodies to HepB were higher in HEU than in HUU infants. Both groups responded similarly to tetanus, Hib, and HepB vaccination. HEU demonstrated stronger pertussis vaccine responses, developing protective titers 1 year earlier than HUU patients, and maintained higher anti-tetanus titers at 24 months of age. Vaccine-induced antibodies to measles virus were similar in both groups at all time points. Our results suggest that the current EPI vaccination program as practiced in South Africa leads to the development of vaccine-specific antibody responses that are equivalent in HEU and HUU infants. However, our data also suggest that a large fraction of both HEU and HUU South African infants have antibody titers for several infectious threats that remain below the level of protection for much of their first 2 years of life.